Table 2 Efficacy and safety outcomes of tocilizumab 8 mg/kg monotherapy and combination therapy comprising tocilizumab and a conventional synthetic disease modifying anti-rheumatic drug

 DAS28 < 2.6

1.21

1.09, 1.36

<0.001

1.20

1.07, 1.34

0.002

 ACR20

1.05

0.99, 1.12

0.11

1.05

0.98, 1.11

0.17

 ACR50

1.14

1.03, 1.26

0.008

1.13

1.02, 1.25

0.02

 ACR70

1.19

0.94, 1.51

0.14

1.12

0.95, 1.33

0.19

 AEs

1.08

0.97, 1.21

0.17

1.09

0.86, 1.38

0.48

 SAEs

1.40

1.03, 1.92

0.03

1.34

0.79, 2.27

0.27

 DAS28 < 2.6

8.77

4.10, 18.75

<0.001

10.39

4.38, 24.65

<0.001

 ACR20

2.10

1.48, 2.99

<0.001

2.15

1.45, 3.19

<0.001

 ACR50

3.00

1.80, 4.99

<0.001

3.24

1.82, 5.78

<0.001

 ACR70

5.32

2.31, 12.25

<0.001

6.23

2.29, 16.93

<0.001

 AEs

1.12

1.06, 1.18

<0.001

1.14

1.07, 1.20

<0.001

 SAEs

1.21

0.91, 1.60

0.19

1.13

0.80, 1.60

0.48

 DAS28 < 2.6

3.95

2.23, 7.00

<0.001

4.50

2.34, 8.64

<0.001

 ACR20

1.68

1.21, 2.32

0.002

1.71

1.18, 2.48

0.005

 ACR50

1.87

1.19, 2.95

0.007

2.01

1.18, 3.42

0.01

 ACR70

2.11

1.18, 3.78

0.01

2.49

1.29, 4.81

0.007

 AEs

1.08

1.01, 1.15

0.03

1.13

0.92, 1.39

0.24

 SAEs

1.21

0.87, 1.69

0.26

1.37

0.64, 2.93

0.42